The fuzzy world of precision medicine: deliberations of a precision medicine tumor board

Aim: To understand how a cancer precision medicine tumor board (CPM-TB) made choices about return of results. Materials & methods: Observed CPM-TB deliberations and completed in-depth interviews with committee members. Results: Responding to complex evidence of ambiguous significance, deliberations of the CPM-TB were predicated on analytic validity and clinical utility. Members had concerns both about potential harms due to returning results based on weak evidence and about withholding potentially meaningful results. Group dynamics and the clinical experiences of individual committee members shaped their work. Conclusion: Both scientific evidence and the social context surrounding deliberations of a CPM-TB influenced decisions about return of results. Subjective elements, while present in any scientific endeavor, may carry more weight in the face of ambiguous findings.

• Publication year

  2016

• Venue

  Personalized Medicine

• Publication date

  2016-12-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.2217/pme-2016-0074PMID 28757884PMCID 5480788
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine.

  2016cited by this paper
• The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine

  2016cited by this paper
• Oncologists' and Cancer Patients' Views on Whole-Exome Sequencing and Incidental Findings: Results from The CanSeq Study

  2016cited by this paper
• Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors.

  2016cited by this paper
• All aboard: Will molecular tumor boards help cancer patients?

  2015cited by this paper
• Trust in standards: Transitioning clinical exome sequencing from bench to bedside

  2015cited by this paper
• Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth.

  2015cited by this paper
• Precision medicine--personalized, problematic, and promising.

  2015cited by this paper
• A new initiative on precision medicine.

  2015cited by this paper
• Molecular tumor board: the University of California-San Diego Moores Cancer Center experience.

  2014cited by this paper
• Testing devices or experimental systems? Cancer clinical trials take the genomic turn.

  2014cited by this paper
• The Genome Clinic: A Multidisciplinary Approach to Assessing the Opportunities and Challenges of Integrating Genomic Analysis into Clinical Care

  2014cited by this paper
• Behind Closed Doors: IRBs and the Making of Ethical Research

  2013cited by this paper
• Translating genomics in cancer care.

  2013cited by this paper
• Lessons from the cancer genome.

  2013cited by this paper
• On being “actionable”: clinical sequencing and the emerging contours of a regime of genomic medicine in oncology

  2013cited by this paper
• Clinical analysis and interpretation of cancer genome data.

  2013cited by this paper
• Return of individual research results and incidental findings: facing the challenges of translational science.

  2013cited by this paper
• Processes and factors involved in decisions regarding return of incidental genomic findings in research

  2013cited by this paper
• Attitudes of patients with cancer about personalized medicine and somatic genetic testing.

  2012cited by this paper
• High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing.

  2012cited by this paper
• Opportunities and challenges for the integration of massively parallel genomic sequencing into clinical practice: lessons from the ClinSeq project

  2012cited by this paper
• Regulating diagnosis in post-genomic medicine: re-aligning clinical judgment?

  2011cited by this paper
• Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study

  2011cited by this paper
• Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.

  2011cited by this paper
• New driver mutations in non-small-cell lung cancer.

  2011cited by this paper
• Towards a sociology of diagnosis: reflections and opportunities.

  2011cited by this paper
• Advances in understanding cancer genomes through second-generation sequencing

  2010cited by this paper
• Clinical implications of the cancer genome.

  2010cited by this paper
• Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results

  2008cited by this paper
• K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

  2008cited by this paper
• Qualitative data analysis for health services research: developing taxonomy, themes, and theory.

  2007cited by this paper
• Developing and Implementing a Triangulation Protocol for Qualitative Health Research

  2006cited by this paper
• Impact of group structure and process on multidisciplinary evidence-based guideline development: an observational study.

  2002cited by this paper

• Factors Associated With Implementation of Biomarker Testing and Strategies to Improve Its Clinical Uptake in Cancer Care: Systematic Review Using Theoretical Domains Framework

  2025cites this paper
• The Role of Algorithms in Molecular Tumour Boards—Managing the Gap Between Research and Clinic in Precision Medicine

  2025cites this paper
• Histology agnosticism: Infra-molecularizing disease?

  2024cites this paper
• Therapeutic biomarkers in acute myeloid leukemia: functional and genomic approaches

  2024cites this paper
• Patients’ and professionals’ views related to ethical issues in precision medicine: a mixed research synthesis

  2021cites this paper
• Radioresistance of Human Cancers: Clinical Implications of Genetic Expression Signatures

  2021cites this paper
• Implementing a clinical cutting-edge and decision-making activity: an ethnographic teamwork approach to a molecular tumorboard

  2020cites this paper
• Molecular matching and treatment strategies for advanced stage lung cancer at Dartmouth-Hitchcock Medical Center: A three-year review of a Molecular Tumor Board

  2020cites this paper
• Differences in cancer patients' and clinicians' preferences for disclosure of uncertain genomic tumor testing results.

  2020cites this paper
• Genomic Strategies for Personalized Cancer Therapy

  2020cites this paper
• Predictive article recommendation using natural language processing and machine learning to support evidence updates in domain-specific knowledge graphs

  2020cites this paper
• Introduction

  2020cites this paper
• Referrals to a Phase I Clinic and Trial Enrollment in the Molecular Screening Era.

  2019cites this paper
• Genomic expertise in action: molecular tumour boards and decision-making in precision oncology.

  2019cites this paper
• Personalized Medicine: Foreword.

  2018cites this paper
• Interactive or static reports to guide clinical interpretation of cancer genomics

  2018cites this paper
• Applying Precision Oncology Principles in Radiation Oncology.

  2018cites this paper
• Evaluating Clinical Genome Sequence Analysis by Watson for Genomics

  2018cites this paper
• Ethical considerations in genomic testing for hematologic disorders.

  2017cites this paper